Narcolepsy Drugs Market to Hit Revenue Worth over US$6.5 Bn Through 2026 End

London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Constant rise in need for effective therapeutics for narcolepsy is primarily expected to drive the growth of narcolepsy drugs market. Moreover, the consistent rise in awareness levels about the narcolepsy diagnosis, and treatment will further contribute toward the growth of narcolepsy drugs market. A new Fairfield Market Research report projects an excellent growth prospect for narcolepsy drugs market during 2021 – 2026. Global narcolepsy drugs market size is expected to see healthy expansion at around 11.2% CAGR over the period of forecast. Up from the revenue of US$3.8 Bn attained in 2021, the market valuation is likely to reach over US$6.5 Bn by 2026 end. Growing role of healthcare providers, governments, patient advocacy groups, and public welfare association groups will continue to be pivotal in strengthening narcolepsy drugs market, says the report. Rapidly building awareness around the symptoms and early diagnosis of narcolepsy is likely to accelerate the growth of narcolepsy drugs market. Moreover, extensive research around narcolepsy, several other sleep disorders, and all the associated environmental and genetic factors will further boost drug supply in long term.

Get the Sample Copy of Report at: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market/request-sample

Key Research Insights

• Global narcolepsy drugs market size will expand at more than 11% CAGR, exhibiting around 1.7x expansion between 2021 and 2026
• Sodium oxybate remains dominant with nearly 52% market share
• Type 1 narcolepsy (with cataplexy) continues to account for a market value share of more than 68% in 2021
  
  

Insights into Segmental Analysis

The selective serotonin Sodium Oxybate remains the most sought-after prescription drug, whereas Nuvigil, and Provigil are due for patent expiry. The report however anticipates the stimulants to lose their market value share in the near future. Xyrem that has been considered as the gold standard (recommended by the American Academy of Sleep Medicine (ASSM)) is a popular FDA-approved drug against the most commong symptoms like cataplexy with associated excessive daytime sleepiness (EDS). Xyrem is expected to enjoy noteworthy commercial success, which will further be favoured by the supportive reimbursement coverage for Xyrem under both the Medicaid, and Medicare.

Key Report Highlights

• New drug approvals provide strong tailwinds to narcolepsy drugs market
• Prevalence of type 2 narcolepsy is increasing rapidly despite continued dominance of type 1 narcolepsy
• Due to the lack of FDA-approved drugs, treatment against paediatric narcolepsy co area of continues to be an area of concern in long run
  
  

Insights into Regional Analysis

Regional analysis that has been presented in the narcolepsy drugs market report reveals that North America, and Europe will continue to be at the forefront in terms of sales. While North America is expected to reap the benefit from the highest narcolepsy prevalence, the market here will continue to largely benefit from the key supporting factors, i.e., greater healthcare spending, strong presence of globally leading players, and favourable reimbursement policy structure. A robust clinical pipeline further keeps the narcolepsy drugs market here, afloat. A sizeably large population continues to live with at least one sleep-related condition, which is projected to keep the scope of growth higher for North American market. Europe also will remain a key market according to the report in light of the H1N1 influenza pandemic that had caused an upsurge in prevalence of sleep disorders. On the other hand, Asia Pacific will also develop a strong potential market for narcolepsy drugs, led by India, China, and Japan.

Key Players

Novartis AG, Teva Pharmaceutical Industries Ltd., GrayMark Healtcare Inc., Addrenex Pharmaceuticals, BIOPROJET, Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Shionogi Inc., Mylan N.V., Ligand Pharmaceuticals, Inc., Shire

Do You Have Any Query or Specific Requirement? Request for Custom Research: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market/request-customization

REPORT SCOPE

Market Segmentation

Therapeutics

• Psychostimulants
• Tricyclic Antidepressants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitors
• Others
  
  

Narcolepsy Type

• Cataplexy
• Without Cataplexy

Geographical Coverage

• North America
• Europe
• Latin America
• Middle East & Africa

Leading Companies

• Jazz Pharmaceuticals, Inc.
• Harmony Biosciences
• Avadel Pharmaceuticals plc
• Axsome Therapeutics, Inc.
• Arena Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Teva Pharmaceutical Industries Ltd.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.
  
  

Report Inclusions

• Market Estimates and Forecast
• Market Dynamics
• Industry Trends
• Competition Landscape
• Therapeutics-wise Analysis
• Narcolepsy Type-wise Analysis
• Region-wise Analysis
• Country-wise Analysis
• Key Trends Analysis
• COVID-19 Impact Analysis

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

Contact

Fairfield Market Research
London, UK
UK +44 (0)20 30025888   
USA (Toll-free) +1 (844) 3829746 
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com